Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tuesday, 29 August 2017

The new anti-cancer drug, OMO-1, was given to the first cancer patient in the world last week in Oxford University’s Early Phase trials unit. Dr Sarah Blagden (Oxford’s ECMC lead and Director of the Early Phase Trials Unit) is Chief Investigator of this Phase I/II study of the combined c-MET/ OCT-1 inhibitor OMO-1 that was outlicenced from Janssen Pharmaceutica to be developed by the Belgian life science company OCTIMET Oncology NV.

Dr Blagden says “it is great to be able to offer our patients new therapies that could be the game-changers of the future.” The centre will be enrolling patients with advanced cancer into this study until Q3, 2018. 

Timothy Perera, CEO of OCTIMET says “We are pleased to reach this important milestone within 7 months of obtaining funding. We look forward to accelerating the development of this agent so that we can bring another personalised therapeutic option for patients in areas of unmet medical need.”

The next patient to enter the study is due to start treatment, also in Oxford, later this week.

Read on Oncology web site

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.